SLC5A2 and hydrops fetalis: SGLT2 inhibitors (as dapagliflozin) are currently the only therapy indicated for all HF patients to improve prognosis, irrespective of LVEF; it also can reduce cardiovascular events and mortality in HF patients [18,26].